2.10
price up icon2.44%   0.05
after-market Handel nachbörslich: 2.08 -0.02 -0.95%
loading
Schlusskurs vom Vortag:
$2.05
Offen:
$2.06
24-Stunden-Volumen:
1.08M
Relative Volume:
0.77
Marktkapitalisierung:
$402.71M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-54.70M
KGV:
-6.3636
EPS:
-0.33
Netto-Cashflow:
$-51.36M
1W Leistung:
-4.11%
1M Leistung:
-12.50%
6M Leistung:
-31.60%
1J Leistung:
-51.16%
1-Tages-Spanne:
Value
$2.03
$2.14
1-Wochen-Bereich:
Value
$1.98
$2.29
52-Wochen-Spanne:
Value
$1.89
$5.11

Savara Inc Stock (SVRA) Company Profile

Name
Firmenname
Savara Inc
Name
Telefon
51285113796
Name
Adresse
6836 BEE CAVE ROAD, AUSTIN, TX
Name
Mitarbeiter
59
Name
Twitter
@SavaraPharma
Name
Nächster Verdiensttermin
2025-03-26
Name
Neueste SEC-Einreichungen
Name
SVRA's Discussions on Twitter

Vergleichen Sie SVRA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SVRA
Savara Inc
2.10 402.71M 0 -54.70M -51.36M -0.33
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Savara Inc Stock (SVRA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-29 Herabstufung H.C. Wainwright Buy → Neutral
2024-12-20 Eingeleitet Wells Fargo Overweight
2024-11-13 Herabstufung Evercore ISI Outperform → In-line
2024-02-15 Eingeleitet JMP Securities Mkt Outperform
2023-11-07 Eingeleitet Guggenheim Buy
2023-05-16 Hochstufung Jefferies Hold → Buy
2023-03-31 Herabstufung Jefferies Buy → Hold
2021-03-16 Eingeleitet Piper Sandler Overweight
2021-03-15 Eingeleitet Oppenheimer Outperform
2019-06-13 Bestätigt H.C. Wainwright Buy
2019-06-13 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2019-06-13 Herabstufung Ladenburg Thalmann Buy → Neutral
2018-08-13 Fortgesetzt ROTH Capital Neutral
2018-01-03 Eingeleitet Ladenburg Thalmann Buy
2017-09-27 Fortgesetzt ROTH Capital Buy
2017-09-22 Eingeleitet Jefferies Buy
2017-09-11 Eingeleitet JMP Securities Mkt Outperform
Alle ansehen

Savara Inc Aktie (SVRA) Neueste Nachrichten

pulisher
Jun 18, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc.SVRA - Bluefield Daily Telegraph

Jun 18, 2025
pulisher
Jun 18, 2025

Insiders Who Purchased US$783.7k Of Savara Stock May Not Have Expected 12% Tumble - simplywall.st

Jun 18, 2025
pulisher
Jun 14, 2025

Savara’s SWOT analysis: biotech firm’s stock poised for growth with aPAP drug - Investing.com

Jun 14, 2025
pulisher
Jun 13, 2025

Savara Inc (NASDAQ:SVRA) Stake Reduced by California State Teachers Retirement System - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $482,000 Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World

Jun 12, 2025
pulisher
Jun 09, 2025

Savara Inc (NASDAQ:SVRA) Shares Sold by Bank of America Corp DE - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Ameriprise Financial Inc. Takes Position in Savara Inc (NASDAQ:SVRA) - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

Jane Street Group LLC Decreases Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

savara elects board members and approves proposals at annual meeting - Investing.com Australia

Jun 07, 2025
pulisher
Jun 06, 2025

savara elects board members and approves proposals at annual meeting By Investing.com - Investing.com South Africa

Jun 06, 2025
pulisher
Jun 06, 2025

Savara Re-elects Board Members at Annual Meeting - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

Savara Inc (NASDAQ:SVRA) Shares Bought by Squarepoint Ops LLC - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

FDA Requests Additional Data for Savara’s MOLBREEVI Application - MSN

Jun 05, 2025
pulisher
Jun 05, 2025

Savara assumed with an Outperform at Oppenheimer - MSN

Jun 05, 2025
pulisher
Jun 05, 2025

Nuveen Asset Management LLC Sells 30,766 Shares of Savara Inc (NASDAQ:SVRA) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Savara Inc. to Present at Jefferies Global Healthcare Conference on June 4, 2025 - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Millennium Management LLC Grows Stake in Savara Inc (NASDAQ:SVRA) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Savara Inc (NASDAQ:SVRA) Shares Bought by ProShare Advisors LLC - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc.SVRA - FinancialContent

Jun 02, 2025
pulisher
Jun 02, 2025

Insider Buying Alert: Joseph Mccracken Acquires Additional Shares of Savara Inc (SVRA) - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Oppenheimer assumes Savara stock at outperform, sets $5 price target - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

Oppenheimer assumes Savara stock at outperform, sets $5 price target By Investing.com - Investing.com Canada

Jun 02, 2025
pulisher
Jun 02, 2025

Oppenheimer Adjusts Price Target on Savara to $5 From $15, Maintains Outperform Rating - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Oppenheimer Maintains Optimism for Savara (SVRA) Despite Filing Setback | SVRA Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Savara director Joseph McCracken buys $20,825 in stock By Investing.com - Investing.com South Africa

Jun 02, 2025
pulisher
Jun 02, 2025

Savara director Joseph McCracken buys $20,825 in stock - Investing.com Australia

Jun 02, 2025
pulisher
Jun 02, 2025

What is HC Wainwright’s Forecast for Savara FY2026 Earnings? - Defense World

Jun 02, 2025
pulisher
May 31, 2025

Savara Inc (NASDAQ:SVRA) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

May 31, 2025
pulisher
May 31, 2025

What is HC Wainwright’s Forecast for Savara FY2029 Earnings? - Defense World

May 31, 2025
pulisher
May 31, 2025

Savara Inc. Grants Equity Awards to New Employees - MSN

May 31, 2025
pulisher
May 30, 2025

FDA Denies Langhorne-Based Savara Application for Rare Lung Disease Treatment - BUCKSCO.Today

May 30, 2025
pulisher
May 30, 2025

Did Savara Inc. (SVRA) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire

May 30, 2025
pulisher
May 30, 2025

Savara (NASDAQ:SVRA) Lowered to “Neutral” Rating by HC Wainwright - Defense World

May 30, 2025
pulisher
May 29, 2025

SVRA: Savara Downgraded by HC Wainwright & Co. | SVRA Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Savara stock rating cut to Neutral by H.C. Wainwright - Investing.com Nigeria

May 29, 2025
pulisher
May 29, 2025

HC Wainwright & Co. Downgrades Savara (SVRA) - MSN

May 29, 2025
pulisher
May 29, 2025

This Starbucks Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga

May 29, 2025
pulisher
May 29, 2025

HC Wainwright Downgrades Savara to Neutral From Buy, Adjusts Price Target to $2 From $6 - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

H.C. Wainwright Lowers Savara (SVRA) Outlook Following FDA Setba - GuruFocus

May 29, 2025
pulisher
May 29, 2025

H.C. Wainwright Lowers Savara (SVRA) Outlook Following FDA Setback | SVRA Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Savara stock price target cut to $2 at Evercore ISI By Investing.com - Investing.com Canada

May 29, 2025
pulisher
May 29, 2025

Savara Inc (NASDAQ:SVRA) Shares Bought by D. E. Shaw & Co. Inc. - Defense World

May 29, 2025
pulisher
May 29, 2025

Guggenheim Reaffirms “Buy” Rating for Savara (NASDAQ:SVRA) - Defense World

May 29, 2025
pulisher
May 29, 2025

Savara (NASDAQ:SVRA) Given New $2.00 Price Target at Evercore ISI - Defense World

May 29, 2025
pulisher
May 29, 2025

Savara (NASDAQ:SVRA) Price Target Lowered to $7.00 at Wells Fargo & Company - Defense World

May 29, 2025
pulisher
May 29, 2025

SVRA ALERT: Levi & Korsinsky Investigates Savara Inc. on Behalf of Shareholders Who Lost Money - ACCESS Newswire

May 29, 2025
pulisher
May 28, 2025

Savara Showcases Promising Phase 3 Trial Data for Molgramostim at ATS 2025 - MSN

May 28, 2025

Finanzdaten der Savara Inc-Aktie (SVRA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Savara Inc-Aktie (SVRA) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
McCracken Joseph S
Director
May 29 '25
Buy
2.08
10,000
20,825
260,837
RAMSAY DAVID A
Director
Mar 31 '25
Buy
2.77
150,000
416,250
2,513,642
Lowrance David L
Chief Financial Officer
Dec 16 '24
Sale
3.33
25,000
83,278
381,005
Pauls Matthew
CHIEF EXECUTIVE OFFICER
Dec 16 '24
Sale
3.31
54,702
180,828
1,536,379
Hawkins Richard J
Director
Dec 16 '24
Sale
3.32
8,000
26,569
67,241
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):